Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Qiagen N.V. (QGEN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 6,625,500
  • Shares Outstanding, K 234,090
  • Annual Sales, $ 1,281 M
  • Annual Income, $ 127 M
  • 36-Month Beta 1.13
  • Price/Sales 5.02
  • Price/Book 2.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.40 +0.18%
on 01/24/17
28.98 -5.28%
on 01/11/17
-0.37 (-1.33%)
since 12/23/16
3-Month
23.94 +14.66%
on 11/02/16
28.98 -5.28%
on 01/11/17
+1.56 (+6.03%)
since 10/24/16
52-Week
19.94 +37.66%
on 06/27/16
28.98 -5.28%
on 01/11/17
+4.79 (+21.14%)
since 01/22/16

Most Recent Stories

More News
First Week of QGEN March 17th Options Trading

Investors in Qiagen N. .

QGEN : 27.44 (-1.29%)
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite

QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.

QGEN : 27.44 (-1.29%)
ICUI : 134.95 (+1.81%)
ALGN : 91.71 (-0.36%)
NSTG : 17.60 (+0.34%)
QIAGEN Enhances Bioinformatics Portfolio with Acquisition of OmicSoft

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of OmicSoft Corporation, providing access to OmicSoft's powerful multi-omics data management infrastructure solution...

QGEN : 27.44 (-1.29%)
QIAGEN Submits QuantiFERON®-TB Gold Plus for U.S. Regulatory Approval

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the submission of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of the modern blood test for detecting tuberculosis...

QGEN : 27.44 (-1.29%)
Qiagen Poised on Fundamentals, Expansion Plans on Track

On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).

BVX : 3.84 (unch)
NXTM : 25.93 (-0.27%)
BAX : 45.84 (-0.39%)
QGEN : 27.44 (-1.29%)
Clinical Laboratory Services Market Growth Due to Demand for Early Diagnosis

http://www.Financialbuzz.com - While it is known that the global healthcare sector is booming due to technological innovations and growth in emerging markets, a less popular yet crucial sub-market is the...

A : 47.35 (-0.08%)
BSX : 23.55 (-0.55%)
QGEN : 27.44 (-1.29%)
PBIO : 0.1599 (-10.17%)
DHR : 80.03 (+0.04%)
QIAGEN Welcomes New Evidence-Based Tuberculosis Testing Guidelines from U.S. Professional Societies

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today welcomed new evidence-based guidelines for TB screening that have broadened the preferential recommendation for the use of modern blood-based...

QGEN : 27.44 (-1.29%)
Mass Spectrometry Adopted by Clinical Laboratories Around the World

Mass spectrometry (MS) is a highly selective analytic technique which provides significantly more accurate measurements and as a result, is now being used in an increasing number of clinical laboratories....

ILMN : 166.00 (+3.18%)
TMO : 140.96 (-1.28%)
QGEN : 27.44 (-1.29%)
PBIO : 0.1599 (-10.17%)
DHR : 80.03 (+0.04%)
QIAGEN GeneReader NGS System to Relaunch in U.S. Market

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the world's first complete Sample to Insight...

QGEN : 27.44 (-1.29%)
QIAGEN's GeneReader NGS System Streamlines Data Management for Labs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with lab informatics company Genohm to empower GeneReader NGS System users with seamless data management by integrating...

QGEN : 27.44 (-1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

See More

Support & Resistance

2nd Resistance Point 27.97
1st Resistance Point 27.89
Last Price 27.44
1st Support Level 27.72
2nd Support Level 27.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.